SCYNEXIS Stock

SCYNEXIS EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of SCYNEXIS (SCYX) as of Aug 9, 2026 is 0.38. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -0.42 — a change of -190.08% (higher).

EV/EBITDA

0.38

YoY

-190.08%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of SCYNEXIS is 2026 0.38 . EV/EBITDA (Enterprise Value to EBITDA) of SCYNEXIS was 2025 -0.42 . It decreases by -190.08% higher compared to the previous year.
Access this data via the Eulerpool API

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCYNEXIS stock

EV/EBITDA (Enterprise Value to EBITDA) of SCYNEXIS is 0.38 in 2026.

EV/EBITDA (Enterprise Value to EBITDA) of SCYNEXIS changed from -0.42 to 0.38, representing a -190.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s SCYNEXIS with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — SCYNEXIS

All Key Metrics — SCYNEXIS